non-small lung cancer
Conditions
Interventions
Granule group:Fuzheng Kangai granule + PD-1 inhibitor
Decoction group:Fuzheng Kangai decoction + PD-1 inhibitor
Placebo group:Placebo(granule or decoction) + PD-1 inhibitor
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. According to the 8th TNM classification of lung cancer edited by International Association for the Study of Lung Cancer (IASLC) and American Joint Committee on Cancer(AJCC),patients are unable to accept surgical resection without sensitising diver alterations(or resistance to targeted treatment)with histologically or cytologically confirmed NSCLC,regardless of arbitrary or unknown PD-L1 expression,accepting PD-L1 inhibitor regimens(including posterior line therapy).2. Range in Age is from 18 to 80 years old. 3. Life expectancy is over 3 months. 4. The investigator confirmed the presence of at least one measurable lesion according to RECIST 1.1 criteria. 5. Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1. 6. Hematologic function was sufficient, defined as neutrophil absolute count >=1.5*10^9/L, platelet count >=100*10^9 /L, hemoglobin >=90g/L (no history of blood transfusion within 7 days) 7. Liver function was sufficient, defined as total bilirubin levels = 60 mL /min (Cockcroft-Gault formula); 9. The function of blood clotting was sufficient, defined as international standardized ratio (INR) or prothrombin time (PT) <=1.5 ULN. If the subject is receiving anticoagulant therapy, as long as PT is in the prescribed anticoagulant range, it is acceptable. 10. For female subjects of reproductive age, a negative urine or serum pregnancy test should be presented within 3 days prior to receiving the first study drug. If the urine pregnancy test results cannot be confirmed as negative, a blood pregnancy test is required 1. Sign written informed consent to participate in the study voluntarily.
Exclusion criteria
Exclusion criteria: 1. Currently participating in an interventional clinical study or receiving another study drug or study device within 4 weeks prior to initial dosing. 2. Prior treatment: drugs that target another stimulating or co-inhibiting T-cell receptor (e.g., CTLA-4, OX-40, CD137). 3. Major surgery was performed within 3 weeks prior to administration. 4. There are active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction, and peritoneal metastasis requiring clinical intervention. 5. A solid organ or blood system transplant has been received. 6. There is clinically uncontrollable pleural effusion or abdominal effusion (patients who do not need drainage effusion or who stop drainage for 3 days without significant increase in effusion can be included in the group). 7. The tumor compresses important surrounding organs such as the esophagus with associated symptoms. 8. Grade III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmia. 9. Severe infection should be treated with antibiotics. 10. Known allergic reactions to the active ingredients of pD-1 inhibitors and or to any excipients. 11. An active autoimmune disease requiring systemic treatment (e.g., use of disease-modifying agents, corticosteroids, or immunosuppressants) developed within 2 years prior to initial administration. 12. Patients requiring long-term systemic corticosteroid use. Patients requiring intermittent use of bronchodilators, inhaled corticosteroids, or topical corticosteroids for COPD or asthma may be enrolled. 13. Symptomatic central nervous system metastases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate;overall survival;disease control rate;1-year survival rate;quality of life; | — |
Countries
China
Contacts
Public ContactWanyin Wu
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed